ALS TDI Research Center

Clinical Trials

No effective ALS treatments are currently available in the marketplace. But today's clinical trials may lead to tomorrow's cure.

Recent Trial Launches:

Research Feed

  • TDI-197 4/11/13 - New lead added targeting UPR.
  • TDI-196 4/11/13 - New lead added targeting immune system.
  • TDI-185 4/11/13 - PD/PK data produced in vivo using this small molecule targeting autophagy and the proteosome is being analyzed at TDI.
  • TDI-178 4/11/13 - TDI analyzing data from PK/PD studies completed on this small molecule neurotrophin.
  • TDI-176 4/11/13 - In vivo efficacy/survival studies completed and analysis began (Regensance partnership)

Research Pipeline

We screen at least 25 therapeutics every year. Here's what's happening in the lab right now:

TDI-144 - 2/10/12 - We moved this small molecule targeting cellular stress into the analysis phase
TDI-143 - November 2012 - This biologic targeting endothelial cell dysfunction moved into the analysis phase following completion of a second round of in vivo survival studies.
TDI-178 - 4/11/13 - TDI analyzing data from PK/PD studies completed on this small molecule neurotrophin.

Stats from the Lab

100

TDP43 mice used each month

1000

transcriptome analyzed each year

20

complete PK studies each year